Filing Flows › Biogen (BIIB) › SPINRAZA revenue
Biogen (BIIB) SPINRAZA revenue by quarter
Biogen's SPINRAZA revenue was $461M in Q3 2026 (third quarter 2026), +15% from Q2 2026. Over the last 6 quarters it ranged from $374M (Q1 2026) to $461M (Q3 2026).
| Quarter | SPINRAZA revenue | Q/Q | Y/Y |
|---|---|---|---|
| Q3 2026 | $461M | +15% | +23% |
| Q2 2026 | $402M | +7% | +2% |
| Q1 2026 | $374M | 0% | -12% |
| Q3 2025 | $374M | -5% | — |
| Q2 2025 | $393M | -7% | — |
| Q1 2025 | $424M | — | — |
Q3 2026 at a glance
Biogen, Q3 2026: revenue $2.8B (+11% year over year), operating margin -0.3%, net loss $20.6M, operating cash flow $641M. The chart follows the revenue to costs, profit and cash.
Questions
What is Biogen's SPINRAZA revenue?
Biogen's SPINRAZA revenue was $461M in Q3 2026 (third quarter 2026), +15% from Q2 2026.
How has Biogen's SPINRAZA revenue changed?
Over the last 6 quarters it ranged from $374M (Q1 2026) to $461M (Q3 2026).